Macrogenics (MGNX) – Hot FDA News
-
Macrogenics (MGNX) Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
-
Macrogenics (MGNX) OS Results from SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer Did Not Demonstrate Statistically Significant Advantage
-
-
-
-
-
-
Back to MGNX Stock Lookup